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ABSTRACT 
 
 Ependymin (EPN) is a neurotrophic factor (NTF) that functions in goldfish long-
term memory formation and optic nerve elongation (Shashoua, 1976; Shashoua, 1977; 
Shashoua, 1985). Goldfish EPN, or CMX-8933 (a short goldfish EPN mimetic studied by 
our lab), surprisingly have several demonstrated effects on mammalian cells, including 
neuroregenerative effects in a rat stroke model (Shashoua et al, 2003), and the activation of 
therapeutic superoxide dismutase (SOD) (Parikh, 2003) and transcription factor AP-1 
(Adams et al, 2003) in mouse neuroblastoma cells or rat primary cortical neuronal cultures.  
Among its various functions, AP-1 can function as a master switch in long-term memory 
consolidation (Sanyal et al, 2002), so it may be a key event in EPN’s mechanism of action.  
AP-1 activation is also a characteristic associated with other full-sized neurotrophic factors, 
including nerve growth factor and brain-derived nerve growth factor. 
This thesis was divided into three parts. The purpose of part I was to determine 
whether our previously observed upregulation of SOD by CMX-8933 is dependent upon 
(or merely concurrent with) AP-1 activation. Four independent SOD immunoblot 
experiments demonstrated that pre-treatment of rat primary cortical cultures with 
trifluoromethyl pyrimidine carboxylate (TFPC), a specific inhibitor of AP-1, significantly 
(p = 0.0004) decreased cellular levels of SOD by 67% at its IC50 concentration of 1 µM, 
and completely inhibited the upregulation at 10 and 100 µM concentrations. Thus, the 
CMX-8933-induced upregulation of SOD appears to depend (directly or indirectly) on AP-
1 activation. 
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 Part II of this thesis included the use of bioinformatics to re-verify exciting recent 
observations that EPN-like proteins exist in mammals, termed mammalian-ependymin-
related proteins or MERPs (Apostolopoulos et al, 2001). If our analyses were convincing, 
human EPN mimetics would then be designed and tested for AP-1 activation. Computer 
alignments and hydropathy plots performed with EPN amino acid sequences deduced from 
gene entries in GenBank verified the existence of mammalian homologs containing highly 
conserved domains with fish EPN’s, suggesting the possibilities of similar protein 
conformation and function. Two human EPN mimetics were designed, hEPN-1 (8 aa long, 
corresponding to the same region as CMX-8933) and hEPN-2 (14 aa long, containing 
CMX-8933 and 6 upstream aa). Several mimetic doses were tested on mouse Neuro-2a 
cultures for nuclear translocation of c-Jun and c-Fos proteins (comprising the AP-1 particle 
upregulated by fish CMX-8933). Seven independent c-Jun immunoblot experiments, and 
five c-Fos experiments, demonstrated a strong (as high as 25-fold) dose-dependent increase 
in the nuclear titers of the AP-1 proteins. Both peptides had statistically equivalent effects.  
Thus, human EPN appears to exist, and two mimetics derived from its sequence appear to 
be biologically active against mouse neuroblastoma cells. Since hEPN-1 and -2 have only a 
few residues in common with CMX-8933, we hypothesize that the mimetic shape rather 
than sequence may be important for biological activity. 
In part III of this thesis, the biological effects of hEPN-1 and hEPN-2 on mouse 
Neuro-2a cells were studied further using RT-PCR to analyze potential increases in specific 
mRNAs. mRNAs related to growth, energy production, and protein translation were tested 
since previous data in our lab (Kaska, 2003) indicated mRNAs for translational elongation 
factor-2 (EF-2), and ribosomal proteins L19 and S12 were upregulated in rat primary 
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cortical cultures by fish mimetic CMX-8933 (Kaska, 2003). Treatment of Neuro-2a cells 
with 1.0 µg/ml hEPN-1 (the highest dose tested for the AP-1 translocation experiments) for 
24 hrs appeared to increase (N = 1) mRNAs for ATP Synthase-C, ribosomal protein L19, 
and translational EF-2, relative to the levels of housekeeper polyubiquitin. Thus hEPN-1 
may be involved in processes related to growth. 
Altogether, the data from this thesis extends our knowledge of fish EPN mimetic 
CMX-8933 (showing that its induction of SOD requires AP-1), demonstrates that human 
EPN may exist (bioinformatics), shows that two human EPN mimetics are biologically 
active (induce AP-1 translocation), and shows that one mimetic hEPN-1 may activate 
several mRNAs related to growth in mouse Neuro-2a cells. 
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BACKGROUND 
 
Neurotrophic Factors     
 
Neurotrophic factors or neurotrophins (NTFs) are naturally occurring proteins that 
promote and control the development, survival, and maintenance of neuronal and glial cells 
(Abe, 2000). NTFs play a key role in the development of both the central and peripheral 
nervous systems (Ikeda et al, 2000). Because of the ability of some NTFs to regenerate 
brain tissue, they are implicated to have potential restorative effects in neurodegenerative 
disorders such as Parkinson’s disease, Alzheimer’s disease and stroke (Sariola et al, 1994).  
 The survival and differentiation of neurons is mainly regulated by target-derived 
neurotrophic factors. Developing neurons that fail to make correct connections will be 
deprived of necessary NTFs and die, whereas neurons that establish correct connections 
survive, differentiate and mature (Connor and Dragunow, 1998; Bear et al, 2001; Stahl, 
2003). 
 NTFs have been shown to alleviate oxidative stress, one of the primary mediators of 
cell damage in neurodegenerative conditions, but the mechanism of how they achieve this 
is unknown. One mechanism by which they accomplish this is to increase cellular levels of 
the anti-oxidative enzyme superoxide dismutase (SOD). EPN (synthetic CMX-8933) has 
been shown by our lab to increase the anti-oxidative enzyme superoxide dismutase SOD 
mRNA and protein levels in rat primary cortical cultures (Parikh, 2003). Short peptides like 
CMX-8933, CMX-9236, NMX-8933 and NMX-9236, that have a combination of 
properties which include the activation of a specific transcription factor AP-1 (Shashuoa et 
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al, 2001) that up-regulates genes that promote synaptic plasticity (Sanyal et al, 2002) and 
the inhibition of intracellular Ca++ accumulation, have been designed by our lab in 
collaboration with Ceremedix Inc., that mimic the action of full-length NTFs, especially 
EPN. EPN is partially cleaved by the proteases that naturally exist in ECF to release an 
active component of 8 amino acid peptide KKETLQFR, like other brain proteins. Our lab 
demonstrated that administration of this sequence in synthetic form (termed CMX-8933) to 
rat primary cortical cells and mouse neuroblastoma cells increases cellular titers of SOD 
(Parikh, 2003). 
 
Ependymin 
Ependymin (EPN) is a secreted glycoprotein component of the extracellular and 
cerebrospinal fluids of the goldfish brain. This protein was first discovered in goldfish 
brains due to its enhanced turnover rates after learning events (Shashoua, 1976; Shashoua 
1977). At first, EPN was thought to be located only in the goldfish central nervous system, 
localized in the zona ependyma from which it derives its name (Shashoua and Benowitz, 
1977; Benowitz and Shashoua, 1979), however later evidence found that it was also 
detected as a novel secretory protein in brain extracellular fluid (ECF), in the cerebrospinal 
fluid (CSF) (Shashoua, 1985) and in the meninges of goldfish and zebrafish brains 
surrounding the ventricles (Hoffmann et al, 1990). 
Ependymin exists in two forms, β and γ (MW 37,000 and 31,000, respectively).  
Ependymin β is glycosylated, and ependymin γ is non-glycosylated (Shashoua, 1976; 
Shashoua, 1985; Konigstorfer et al, 1989; Shashoua et al, 1990). In goldfish, the protein 
portion consists of 216 amino acid residues, including two N-glycosylated sites (Adams 
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and Shashoua, 1994). Both β and γ proteins can bind concanavalin A, and can be isolated 
from the brain extracellular fluid by lectin affinity chromatography (Schmidt and 
Shashoua, 1983).  
Preparations of ECF proteins from goldfish brains were found to contain proteases 
and esterases (Schmidt and Shashoua, 1983; Shashoua and Holmquist, 1986; Shashoua, 
1985; Shashoua, 1988) that promote the proteolysis of ependymin, releasing specific 
smaller peptides into the ECF (Shashoua, unpublished). This result indicates that 
ependymin might exert its biological activity in vivo via smaller polypeptide fragments.  
EPN β and γ were shown to constitute 14% of the total protein content of the brain 
extracellular fluid, and are also a minor component (0.3%) of serum proteins (Schmidt and 
Shashoua, 1981; Schmidt and Lapp, 1987).   
 
Ependymin’s Function 
EPN is a multi-functional protein. Although the precise molecular mechanism by 
which the brain uses EPN remains unknown, certain functional aspects of EPN closely 
resemble the properties of other NTFs, such as involvement in synaptic biochemical 
changes associated with long-term memory consolidation, optic nerve elongation, and 
neuronal growth (Shashoua and Moore, 1978; Schmidt, 1987; Piront and Schmidt, 1988; 
Schmidt et al, 1995; Schmidt, 1995). Addition of goldfish EPN to mouse neuroblastoma 
NB2a cell cultures enhances neurite sprouting and extension (Shashoua et al, 1992), a 
phenomenon also observed with NGF (Conner and Varon, 1995) and BDNF (Patel and 
McNamara, 1995). Injection of anti-EPN Ab can block memory formation (Schmidt and 
Shashoua, 1988). In addition, EPN has been linked with learning (Shashoua, 1985; Piront 
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and Schmidt, 1988; Shashoua and Hesse, 1989; Rother et al, 1995), acclimation to the cold 
(Tang et al, 1999), optic nerve regeneration and neuroplasticity (Shashoua, 1985; Schmidt 
and Shashoua, 1988; Shashoua, 1988; Shashoua, 1991), and neuronal growth (Schmidt and 
Shashoua, 1988; Schmidt et al, 1991).  
 
Ependymin Peptide Therapy:  CMX-8933 
 NTFs have been studied as potential therapeutics for neurodegenerative diseases, 
heart attacks, and strokes. Because full-length NTFs inefficiently cross the Blood Brain 
Barrier (BBB), our laboratory in collaboration with Ceremedix Inc. has been investigating 
small peptide mimetics of EPN as potential therapeutics. Our best characterized mimetic is 
peptide CMX-8933 (amino acids KKETLQFR), corresponding to positions 78-85 in the 
mature goldfish EPN sequence (see Figure 1). This sequence was chosen because its 6-
amino acid C-terminal portion (ETLQFR) is reproducibly generated when pure EPN is 
incubated with trypsin (Shashoua, 1991) or goldfish ECF (which naturally contains 
proteases; Shashoua, unpublished), and protease cleavage consensus sites exist nearby 
(Adams et al, 1996).  So this CMX-8933 peptide appears to exist biologically. 
 
Figure 1 - Rationale for the Design of Therapy Peptide CMX-8933. The completely conserved 8 amino 
acid sequence of CMX-8933, represented in red, is a proteolytic cleavage product of a 215 aa long Goldfish 
EPN, present in ECF. Charged amino acids are indicated by ‘+’ or ‘-’ above the sequence (Adams et al, 1996; 
Adams et al, 2003). 
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The CMX-8933 sequence is completely conserved among the six deduced protein 
sequences of the order Cypriniformes (Adams and Shashoua, 1994; Adams et al, 1996). 
Our working hypothesis is that peptide CMX-8933 may be a biologically active proteolytic 
cleavage product of EPN in the ECF (where full-length EPN is present as well) possibly 
comprising EPN’s receptor-binding domain. Encephalins and endorphins serve as a 
precedent for the proteolytic removal of functional receptor-binding byproduct fragments 
(Goldstein, 1976). 
 
Ependymin Bioinformatics and Mammalian Ependymin-Related Proteins (MERPs) 
Although EPN was originally discovered in goldfish, and that species remains the 
only one in which functional studies have been performed to date, recent bioinformatic 
approaches argue for EPN’s existence outside that species. The rate and pattern of EPN 
DNA evolution was studied (Orti and Meyer, 1996) in other teleost fish including 
Cypriniforms, Siluriforms, Gymnotiforms and Characiforms. It showed that among 25 
different fish species, each presumed EPN protein sequence contains five highly conserved 
cysteine domains (presumed to form disulfide bonds), one completely conserved 
tryptophan domain, and two highly conserved glycosylation sites. Results of this study 
indicated that molecules structurally related (highly conserved functional domains) to the 
very well characterized Cypriniform EPN’s exist, even if their overall sequences are not 
highly conserved. These alignments of fish EPN protein sequences were later extended to 
include a few mammalian species (Apostolopoulos et al, 2001) providing evidence for a 
family of mammalian homologs of ependymin called “ependymin-related proteins” (ERPs) 
(for non-Cypriniform non-mammalian EPNs), and mammalian homologs as “mammalian 
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ependymin-related proteins” (MERPs) (Apostolopoulos et al, 2001). Thus, by extending 
the teleost alignment originally deduced by Orti and Meyer (1996), Apostolopoulos et al 
(2001) identified mammalian EPN-related proteins (MERP’s). 
MERPs are found in the hippocampal and dentate granule cell neurons of brain. The 
entire coding region of human MERP-1 has been cloned and mapped to chromosome 
7p14.1. Mouse MERP-1 and MERP-2 genes have also been cloned (Apostolopoulas et al, 
2001) and mouse MERP-2 has been localized to chromosome 13. Furthermore, monkey 
MERP-1 and frog ERP have also been identified (Apostolopoulas et al, 2001). Another 
novel EPN-related gene, UCC1, highly expressed in colorectal tumor cells (so it may have 
a role in cell growth), also showed significant sequence similarity to the highly divergent 
piscine ependymins (Nimmrich et al, 2001). Sequences for these and additional 
mammalian homologs from monkey and mouse, have recently been added to the GenBank 
database and so it is clear that MERP-1-like genes exist (Gregorio-King et al, 2002).  
Despite relatively low amino acid sequence conservation between piscine 
ependymins, toad ERP, and MERPs, several amino acids (including four key cysteine 
residues) are found to be strictly conserved, and the hydropathy profiles and glycosylation 
sites are remarkably alike, suggesting the possibilities of similar protein conformation and 
function (Orti and Meyer, 1996; Apostolopoulas et al, 2001). As with fish ependymins, 
frog ERP and the MERPs contain a signal peptide typical of secreted proteins. The MERPs 
have been found to be expressed at high levels in several hematopoietic cell lines and in 
nonhematopoietic tissues such as brain, heart, and skeletal muscle, as well as several 
malignant tissues and malignant cell lines (Nimmrich et al, 2001). The complete human 
MERP-1 sequence, composed of 344 amino acid residues, has been very recently 
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characterized and found to be expressed in hematopoietic progenitors and other human 
tissues (Gregorio-King et al 2002). These findings suggest that MERPs have several 
potential roles in a wide range of cells and tissues, so it may function in places other than 
the central nervous system. 
 
Human EPN-1 and Human EPN-2 Peptides 
With the bioinformatic “discovery” of human MERP, our lab decided to investigate 
the possible biological activity of peptides derived from its sequence. The human EPN 
peptide mimetics that I used in this project are two different portions of MERP-1. Human 
EPN-1 (hEPN-1) comprises the 8 amino acid peptide "SKMTLTQP", corresponding to 
positions 234-241 in the mature MERP-1 sequence (see Figure 2), which represents the 
exact same region as CMX-8933’s "KKETLQFR". Only 3 of the amino acids are 
conserved with CMX-8933, but our working hypothesis is that this region might represent 
the same receptor-binding region. The "K" in human EPN-1 is completely conserved in all 
known EPN's.         
MPPRMLVAPLPLHFLLAAVSSENRSGRRQWQQAVAAGSGPGRNSSRAIHWSLPRALVPATGTRASGSQKRQRP
PKGQEALWSRPHSRHSAERAGGSHSDPGRLSAPLGLGLPSGRGRLTAMPGRAPLRTVPGALGAWLLGGLWAWT
LCGLCSLGAVGAPRPCQAPQQWEGRQVMYQQSSGRNSRALLSYDGLNQRVRVLDERKALIPCKRLFEYILLYK
DGVMFQIDQATKQCSKMTLTQPWDPLDIPQNSTFEDQYSIGGPQEQITVQEWSDRKSARSYETWIGIYTVKDC
YPVQETFTINYSVILSTRFFDIQLGIKDPSVFTPSSTCQMAQLEKMSEDCSW        344 aa 
 
Figure 2 – Amino Acid Sequence of Human MERP-1 (Accession Number: AY027862) and Peptide 
Mimetics Tested in This Thesis. The complete 344 aa of Human MERP-1 (Apostolopoulos et al, 2001).  
The 8 amino acids shown in red represent mimetic hEPN-1 which precisely corresponds to the exact same 
region as CMX-8933, and includes a lysine residue (K) conserved in all known EPNs. The 14 amino acids in 
the box represent mimetic hEPN-2 which includes a cysteine residue at site 6 completely conserved in all 
known EPNs. 
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 Human EPN-2 (hEPN-2) comprises the 14 amino acid peptide "QATKQCS-
KMTLTQP", corresponding to positions 228-241 in the mature MERP-1 sequence (see 
Figure 2), which simply extends hEPN-1 upstream to include a cysteine that is also 
completely conserved in all known EPN's. 
 
Activator Protein (AP-1) Transcription Factor 
The activator protein (AP-1) transcription factor family is a ubiquitous, 
fundamental class of transcriptional regulators (Wagner, 2001). In fact, AP-1 was one of 
the first mammalian transcription factors to be identified, but its physiological functions are 
still being unraveled (Angel and Karin, 1991). It is a central component of many signal 
transduction pathways, and is activated in response to an incredible array of stimuli, 
including mitogenic growth factors, inflammatory cytokines, growth factors of the TGF-
beta family, UV and ionizing irradiation, cellular stress, antigen binding, and neoplastic 
transformation (Wisdom, 1999). The pleiotropic nature of a variety of inducers raised an 
issue as to how could AP-1 possibly mediate the cellular response to such a wide array of 
stimuli?  Peptide growth factors (which lead to cell cycle progression) and UV irradiation 
(which leads to cell cycle arrest) appear to be the two most potent inducers of AP-1 activity 
(Wisdom, 1999). AP-1 has been a paradigm for transcription factors, and acts like an 
environmental biosensor (Wagner, 2001). 
 
AP-1 Functions  
AP-1, depending on its exact protein composition, regulates the promoter activity of 
a large number of genes associated with developmental, proliferative, inflammatory, and 
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homeostatic processes in many types of cells. AP-1 is involved in such diverse processes as 
cellular proliferation, transformation, and death (Shaulian and Karin, 2002).  
Biological functions of the dimeric transcription factor complex AP-1, in particular 
in its role in skeletal development, revealed that some components, such as c-Fos, are key 
regulators of bone cell differentiation, whereas others, like c-Jun, JunB and Fra-1 are 
essential in embryonic and/or postnatal development (Wagner, 2001). AP-1’s activation by 
a variety of neurotrophic factors suggests its role in short- to long-term synaptic plasticity 
and memory, and in regulating long-term neural plasticity (Adams et al, 2003). AP-1 is 
activated by other NTFs, such as nerve growth factor (NGF) (Ip et al, 1993; Tong and 
Perez-Polo, 1996) and brain-derived neurotrophic factor (BDNF) (Gaiddon et al, 1996).   
AP-1 is a redox-sensitive transcription factor (Zhang et al, 2002). Cells evolve 
efficient strategies for dealing with stress responses by activating the transcription of genes 
that encode for defense and repair proteins. In yeast, members of the AP-1 family of 
proteins are required for the transcriptional response to oxidative stress. Many of the 
features of this response appear to be evolutionarily conserved (Zhang et al, 2002).  
AP-1 activation has been shown as an important component of brain responses to 
oxidative stress (Tong et al, 2003). Increased expression of AP-1 transcription factors after 
neurotoxin insults is seen in rat hippocampus and cerebellum (Xiao et al, 1999). The 
important structural features of this factor, signaling pathways controlling its activity, and 
the nature of the target genes it control has made AP-1 a very important transcription factor 
(Toone et al, 2001). 
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Components of AP-1 
Biochemical purification showed that AP-1 is not a single transcription factor, but 
instead, a family of related dimeric complexes of Fos and Jun family proteins which are 
required for DNA-binding activity specific for the palindromic sequence 5’ TGAGTCA 3’ 
(Wisdom, 1999). This family appears in virtually all vertebrate cell types. Since the DNA 
recognition sequence is palindromic, DNA recognition occurs only when the Jun and Fos 
form dimeric complexes, which is mediated by the basic-leucine zipper (bZIP) motif to 
bind the AP-1 site in the promoter of target genes, which in turn regulate the expression of 
late response genes that produce long-term changes in cells (Yu et al, 1995). In fact, the 
DNA-binding activity of Jun is increased through its interaction with Fos (Allegretto et al, 
1990). The properties of the Jun and Fos leucine zippers dictate the nature of the dimeric 
complexes that will form: the leucine zipper of Jun family proteins can form homodimeric 
complexes, as well as Jun–Fos heterodimers, while the leucine zipper of Fos proteins is 
capable only of heterodimer formation (Wisdom, 1999). The leucine zipper and DNA-
binding regions are highly conserved among the c-fos and c-jun families of related 
inducible genes. Thus, multiple protein complexes can be formed that may interact with 
AP-1 binding sites in numerous genes to affect gene expression in response to 
environmental signals. (Abate and Curran, 1990). 
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Figure 3 - Activator Protein-1. This diagram depicts the leucine zipper motif (ladder “rungs”) in a 
JUN/FOS heterodimer complex.  Also shown are the basic (positively charged) domains binding to the target 
DNA sequence (Gass et al, 1997). 
 
c-Jun and c-Fos are some of the immediate early genes that are induced within 
minutes to hours in response to perturbations in the cellular environments (Zawia and 
Harry, 1993). Their induction has shown to cause sprouting or synaptic plasticity (Gass and 
Herdegen, 1995). Mostly, c-Jun acts as a positive regulator of cell proliferation unlike other 
members of the family. The growth-promoting activity of c-Jun is mediated by repression 
of tumor suppressors, as well as upregulation of positive cell cycle regulators. Yet it is 
interesting to note that its induced cell growth, for example during development, is not 
always accompanied by tumor growth. 
c-Fos is involved in the response of the brain to the neurotoxin TMT in an age-
dependent and region-specific manner (Zawia and Harry, 1993). The rapid and transient 
expression of c-Fos mRNA after exposure of cells to peptide growth factors indicates AP-1 
is a nuclear target of growth factor signaling pathways (Wisdom, 1999). AP-1 influences a 
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variety of positive and negative cellular processes, which is determined in part by its exact 
protein composition and mechanism of activation (Adams et al, 2003). 
Although we have come a long way from discovering AP-1’s major components, 
we still lack a detailed molecular knowledge of how these factors interact with DNA to 
activate or repress genes in the nucleus. It is also not clear how the response of AP-1 to 
growth factor signaling from the cell surface to the nucleus is interpreted at the molecular 
level, and whether AP-1 is relevant for human disease (Wagner, 2001).  
 
Transcriptional Activation and Translocation of AP-1 
Like most transcription factors, Fos and Jun proteins are modular; the DNA binding 
and transcriptional activation domains are physically separable and are subject to control 
by different signaling pathways. Jun family proteins contain a single activation domain 
located amino-terminal to the bZIP motif. In the case of c-Jun, the activation domain is 
regulated to a large degree by the JNK family of MAP kinases (Karin, 1995). The docking 
site for JNK on c-Jun (the delta domain) is physically separable from the phosphorylation 
sites, and the substrate binding site on JNK is distinct from the active site (Hibi et al, 
1993). One interesting feature of this mechanism is that JNK binding to c-Jun may or may 
not lead to c-Jun phosphorylation.   
Fos family proteins contain activation domains both amino-terminal and carboxy-
terminal to the bZIP motif, which is centrally located. The Fos C-terminal activation 
domains are regulated by phosphorylation, although there is not a lot of information about 
them. Although, the N-terminal activation domains of Fos proteins are required for 
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biological activity, there is no evidence that the function of the N-terminal domain is 
regulated in response to extracellular signaling. 
AP-1 translocation to the nucleus, and binding to promoters containing one or more 
AP-1 binding sites, leads to the transcription of those genes that promote the survival of 
damaged neuronal cells. Stimulation of AP-1 has been shown previously to activate 
neurotrophin genes in addition to being activated by them. 
 
Superoxide Dismutase  
 Superoxide dismutase (SOD) is an anti-oxidative enzyme that catalyzes the 
dismutation of two superoxide anions to hydrogen peroxide and molecular oxygen. The 
toxic hydrogen peroxide is further rapidly reduced by Catalase or Glutathione Peroxidase 
(GPX) into water and molecular oxygen, as shown in Figure 4. SOD is the rate limiting 
enzyme in this pathway (Sun and Chen, 1998; Allen and Tresini, 2000); thus, its 
upregulation is of high therapeutic interest. Superoxide radicals play a detrimental role in a 
variety of neurodegenerative diseases (Venarucci et al, 1999), including stroke, and their 
accumulation ultimately leads to oxidative stress, causing cellular damage and death. The 
rapid breakdown of superoxide anions is needed to minimize overall tissue damage. Over-
expression of SOD in transgenic mice decreases infarct volume following ischemia (Sheng 
et al, 1999a; Sampei et al, 2000) and increases resistance to neurotoxin MPTP (Przedborski 
et al, 1992; Klivenyi et al, 1998). Over-expression of SOD in transgenic rabbits provides 
cardioprotection from myocardial infarction (Li et al, 2001). Levels of c-Jun and c-Fos 
proteins increased in transgenic animals over-expressing SOD, indicating AP-1 may be 
involved in SOD’s neuroprotection against oxidative stress (Huang et al, 2001). Therefore, 
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the application of a peptide able to increase SOD to levels seen in the transgenic animals 
might be therapeutic following heart attacks or strokes.   
 
 
                  Figure 4 - Biological Function of Superoxide Dismutase (SOD). 
 
When designing therapeutics to over-express SOD, it is important to determine 
whether SOD’s over-expression might have deleterious effects. It has been shown in the 
transgenic models that over-expression of SOD by as much as 30-fold in all tissues, not 
only resists ischemia but the animals remain healthy (Przedborski et al, 1992; Chan et al, 
1993; Chan and Kawase, 1998; Sheng et al, 1999b; Li et al, 2001). In addition, SOD has 
been found to have a potential role in deterring the aging process, thus over-expression of 
SOD in transgenic models shows multiple positive effects (Parkes et al, 1998). 
 
Mechanism of Action of Full-Length EPN and EPN-NTF Peptides 
Little is currently known about the exact molecular mechanism in vivo by which the 
brain utilizes full-length EPN or the EPN peptides. CMX-8933, a synthetic peptide created 
to mimic a peptide naturally cleaved from EPN, has been shown by our lab to activate AP-
1. CMX-8933 increased the DNA-binding affinity of two AP-1 nuclear factors (a 
homodimer and a heterodimer) containing c-Jun and c-Fos proteins (Shashoua et al, 2001). 
It also increased the activity of c-Jun N-terminal kinase (JNK) (an enzyme that directly 
activates AP-1), increased the phosphorylation state of c-Jun protein (a component of AP-
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1), and increased the transactivation of synthetic and natural AP-1 dependent promoters 
(Adams et al, 2003). Because AP-1 has been shown to be a master switch that controls 
long-term memory consolidation (Sanyal et al, 2002), and because EPN also functions in 
long-term memory consolidation (Shashoua and Moore, 1978; Schmidt, 1987; Piront and 
Schmidt, 1988; Schmidt et al, 1995) the activation of AP-1 may be a key component of 
EPN’s mechanism of action. 
Based on cumulative data from the Adams and Shashoua labs, we have proposed a 
tentative model for how CMX-8933 activates AP-1 (Figure 5). Since all known growth 
factors and NTFs act via cell surface receptors, EPN may too (Adams et al, 2003). EPN, or 
its proteolytic cleavage products present in the ECF, may interact with an EPN receptor 
present on the surface of neuronal cells, which initiates a signal transduction cascade 
involving the MAP kinase pathway and AP-1 as depicted in Figure 5. Activation of protein 
kinase C (PKC), protein tyrosine kinases (PTKs), and MEK kinase (MEKK) (Hasson, 
1998; Kaska, 2003; inhibition experiments), leads to the activation of JNK kinase (Adams 
et al, 2003; substrate assays). JNK phosphorylates the c-Jun component of AP-1 (Adams et 
al, 2003; c-Jun phospho-westerns), inducing AP-1’s translocation into the nucleus (Hasson, 
1998; Adams et al, 2003; nuclear isolations). A functional nuclear AP-1 (El-Khishin, 1999; 
Adams et al, 2003; luciferase reporter assays) then presumably activates AP-1-dependent 
therapeutic genes, including those for anti-oxidative enzymes SOD (Parikh, 2003), catalase 
(CAT), and glutathione peroxidase (GPX) (Armitstead, 2001). Three of the above MAPK 
components (PKC, PTK, and MEKK) were shown by inhibition experiments to be required 
for SOD upregulation (Kaska, 2003). A key purpose of this thesis was to use an AP-1 
inhibitor to demonstrate that the AP-1 activation is also required for SOD upregulation. 
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Figure 5 - Our Lab’s Working Hypothesis for the Mechanism of Action of Ependymin. The full-length 
EPN sequence and/or the synthetic mimetic 8933 is thought to interact with a receptor on the neuronal cell 
surface activating the MAP kinase pathway, and JNK which phosphorylates the c-Jun component of AP-1 
which translocates into the nucleus and transactivates genes for the antioxidative enzymes, and other 
therapeutic proteins. This is thought to ultimately lead to an increase of antioxidative enzymes within the cell, 
a lowering of oxidative stress, and increased neuronal survival. 
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THESIS PURPOSE 
 
Our lab previously showed that treatment of mouse neuronal cell lines or rat 
primary cortical cultures with peptide CMX-8933 activates several components of the 
MAPK pathway (PKC, PTK, MEKK), increases the phosphorylation of the c-Jun 
component of transcription factor AP-1, increases nuclear translocation of AP-1, increases 
the DNA-binding affinity of AP-1, and increases cellular levels of SOD mRNA and 
protein. Using SOD protein upregulation as an end-point, our lab has recently focused on 
determining which of the above events is required for SOD upregulation. Inhibitors of 
PKC, PTK, and MEKK showed that those three components are required (Kaska, 2003). 
The first part of this thesis will test a new chemical inhibitor of AP-1 transactivation, 
TFPC, to determine whether AP-1 activation is required for SOD upregulation, or is an 
unrelated event.  
The second part of this thesis will test the biological activity of two new peptides 
homologous to a newly “discovered” human mammalian ependymin-related protein 
MERP-1, identified using bioinformatics (Apostolopoulos et al, 2001). The thesis will test 
whether treatment of a mouse neuronal cell line with these human peptides induces the 
translocation of c-Jun and c-Fos (two AP-1 components), and up-regulates mRNAs 
involved in translation and growth, as expected for any NTF that functions in neuronal 
growth. 
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MATERIALS AND METHODS 
 
Murine Neuroblastoma Cell Culture Conditions 
 The neuronal cell line grown and maintained for this project was mouse 
neuroblastoma (Neuro-2a).  It was originally established in 1969 by Klebe and Ruddle 
from a spontaneous brain tumor of a strain-A albino mouse.  These cells were purchased 
frozen from American Type Culture Collection (ATCC) (catalog #CCL-131). This cell line 
is adherent (ATCC, 2003). Other materials used for cell culture included Dulbecco’s 
Modified Eagle’s Medium (DMEM; with glutamine and sodium pyruvate), Trypsin-EDTA 
solution (0.25% Trypsin; 1 mM EDTA), Fetal Bovine Serum (FBS), MEM Non-Essential 
Amino Acids Solution (100x, 10 mM) and Gentamycin (10 mg/ml). All were purchased 
from Invitrogen Life Technologies, Inc. 
 
Complete Medium Preparation 
A 500 ml bottle of DMEM culture medium was supplemented with the following in 
order to make it complete medium (final concentrations are in parentheses): Non-essential 
amino acids (0.1 mM), Fetal Calf Serum (10%), and gentamicin (5 µg/ml). The contents 
were filtered aseptically through a pre-sterilized 500 ml filter using a vacuum pump, then 
mixed briefly. All components used for cell culture were pre-warmed before use in a 37°C 
water bath. 
 
Subculturing 
 
The first step was to thaw the frozen ATCC stock of Neuro-2a cells by rapid (<1 
min) agitation in a 37°C water bath. They were then transferred to a vented T-25 culture 
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flask diluted with 6 ml of complete medium. Flasks were incubated at 37°C in a humidified 
atmosphere containing 5% CO2 overnight, and then the toxic freezing medium containing 
DMSO was replaced with normal complete medium. When the cells reached confluency, 
the medium was removed, and the cells were briefly rinsed with a small volume of 
outdated DMEM stock stored at 4°C. This step was done to remove the FCS proteins. The 
wash was immediately removed, and a small volume (refer to Table 1 for exact amounts) 
of Trypsin-EDTA solution (0.25% Trypsin) was added to just cover the cell monolayer. 
The flask was then incubated at room temp (or 37° C in the incubator) until the cells 
detached, approximately 2 minutes. The cells would come off in white sheets after the 
incubation. An equal amount of fresh complete culture medium was then added to the flask 
so that the FCS in the medium occupies the remaining trypsin. Then the cell suspension 
was transferred to a 15ml plastic tube and centrifuged in a clinical centrifuge (25°C, 5 
minutes, 500 x g) to pellet the cells. The supernatant was then removed, and the cell pellet 
was re-suspended in fresh culture medium, and the cells were dispensed into new sterile 
flasks. 
Table 1- Summary of Various Cell Culture Reagent Volumes 
Flask Type Amt. Used For Trypsinizing Amt. Used For Washes 
Normal Total ml in 
Flask During Culture 
T-25 2 ml 3 ml 6 ml 
T-75 5 ml 10 ml 15 ml 
T-150 7 ml 20 ml 25 ml 
 
 
 The normal split ratio specified by ATCC was 1:3 to 1:6, and this is what was used 
for the most part. Feeding the flasks was normally done twice or three times a week. When 
aliquots were to be frozen, the freezing medium was normal complete culture medium plus 
5% filtered DMSO. A total of 2 ml of cells from two flasks were frozen at -80°C, then 
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moved to liquid nitrogen. One T-25 flask was maintained between experiments. At low 
density, the Neuro-2a cells had a spherical morphology (Figure 6). 
 
Figure 6 – Neuro-2a Cells. The neuro 2a cells are about 25 um in size. Cells were plated at low density and 
visualized under a 40X objective. 
 
For SOD inhibition experiments, rat primary mixed cortical cultures were provided 
by Ceremedix, Inc. For AP-1 translocation experiments and RT-PCRs, mouse Neuro-2a 
cells were used. 
 
CMX-8933 Preparation 
At Ceremedix Inc., CMX-8933 was synthesized by the Merrifield process 
(Shashoua et al, 2001) and purified by HPLC to give a 99.5% pure white solid powder. The 
structure was confirmed by amino acid analysis and mass spectroscopy. Mass spectroscopy 
was also used to verify the absence of trifluroacetic acid. The peptide was converted to its 
acetate salt, and lyophilized to yield a product that was stable for at least three months at 
4°C. Peptide was dissolved in cell culture medium just prior to use. 
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Human EPN Peptides 
Human peptides hEPN-1 and hEPN-2 were purchased from Abbott Laboratories.  
hEPN-1 was stabilized in a solution of 1% BSA, and hEPN-2 was stabilized in complete 
DMEM culture medium. 
 
Drug and Inhibitor Culture Treatments  
For inhibition experiments with AP-1 inhibitor TFPC (Trifluoromethyl pyrimidine 
carboxylate) (Palanki et al, 2000), TFPC (Calbiochem) was added directly to the rat 
primary cortical culture media to make the following final concentrations 0, 0.1, 1, 10 and 
100 uM, as shown in Table 2 (samples 2 – 6), five minutes prior to the addition of CMX-
8933 to 10 ng/ml, then the incubation was continued for 5 hours. The IC50 of TFPC on 
neuronal AP-1 is 1.0 uM (Palanki et al, 2000). Whole cell lysates were then prepared (see 
below) and SOD activity was analyzed by Western Blots. 
Table 2 - CMX-8933 / TFPC Inhibitor Amounts Used 
Samples CMX-8933 TFPC Final Conc (µM) 
1 - 0 
2 + 0 
3 + 0.1 
4 + 1.0* 
5 + 10 
6 + 100 
* = IC50 of TFPC on neuronal AP-1. 
 
For AP-1 translocation experiments with human EPN peptides, nuclear extracts 
were prepared (see below) on seven confluent T-25 flasks. Quiescent (serum-free 12 hr) 
neuroblastoma cells were treated with hEPN-1 (in BSA) or hEPN-2 (in culture medium) to 
make final concentrations of 0.1 ug/ml, 0.2 ug/ml and 1.0 ug/ml, for low, medium and high 
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doses, respectively. The 37˚C incubations were continued for 3 hours prior to extraction of 
nuclei. AP-1 translocation was verified by analyzing the increase in cellular titers of c-Jun 
and c-Fos nuclear proteins by Western Blots. 
For RT-PCR experiments with Human EPN peptides, RNA extractions were done 
on two confluent T-150 flasks. Quiescent (serum-free 12 hr) neuroblastoma cells were 
treated with Human EPN 1 peptide mimetic at a final concentration of 1.0 ug/ml and the 
370C incubations continued for 24 hours prior to isolation of total cellular RNA. Increases 
in mRNA levels were verified by RT-PCR. 
 
Whole Cell Extracts 
Whole cell extracts were prepared from in vitro plated rat primary mixed cortical 
cells in T-25 flasks, in order to obtain protein for immunoblots. 
 
Cell Harvesting 
The flasks were collected and the media was poured off and 10 ml of ice-cold PBS-
EDTA (1X PBS, 20 mM EDTA) was added to each flask. Using a plastic scraper, the cells 
were scraped into the PBS and then removed with a pipette. The suspension was placed in 
15ml conical tubes and pelleted at 500 x g for 5 minutes. The PBS was then discarded, and 
the cell pellet was washed once with ice cold PBS-EDTA, and centrifuged again as 
previously described. Once again the wash was discarded, then the tube was briefly 
inverted onto a towel to get rid of as much of the PBS as possible. Then the tube was 
placed on ice. 
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Cell Lysis 
Once all the PBS wash was removed, 200 µl of Complete Lysis Buffer (20 mM 
HEPES pH 7.9, 10 mM KCl, 300 mM NaCl, 1 mM MgCl2, 0.1% Triton X-100, 20% 
Glycerol, and freshly added 0.5 mM DTT and 0.5 mM PMSF) was added to each pellet 
from one T-25 cultured flask. Using a blue-tip, the cell pellet was re-suspended in the 
buffer and then transferred to 1.5 ml eppendorf tubes on ice. The suspension was incubated 
on ice for at least 10 minutes to thoroughly lyse the cells. 
 
Lysate Clarification 
The pellet was then microcentrifuged at 4˚C for 5 minutes to pellet cell debris. The 
supernatant was put into 0.5 ml eppendorf tubes (about 40 µl per tube) and 1 µl of the 
supernatant was put into 0.5 ml of dH2O for protein determination (1:500) using Coomassie 
Reagent (Pierce).  The tubes were stored at –80˚C. 
 
Protein Determination 
BSA protein standards were prepared (1.25, 2.50, 5.00, 10.00, 20.00, 40.00 µg/ml), 
and 0.5 ml of each was added to 1.5ml eppendorf tubes. A blank was prepared with 0.5 ml 
of dH2O. Next, 1 µl of the sample plus 0.5 ml of dH2O were put into 1.5ml eppendorf 
tubes. All tubes were then put into a water bath for 10 minutes to ensure that all were at the 
same temperature. The tubes were then microcentrifuged, and 0.5 ml of Coomassie 
Reagent (Pierce) was added to all tubes. The tubes were then vortexed to mix. Absorbance 
was read on a spectrophotometer at OD 595 nm zeroed against the dH2O blank.   
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Nuclear Extracts 
Nuclear extracts were prepared from in vitro cultured Neuro-2a cells in T-25 flasks, 
in order to obtain nuclear protein for AP-1 translocation immunoblots. 
 
Cell Harvesting 
The flasks were collected, the media was poured off, and 10 ml of ice-cold PBS-
EDTA (1X PBS, 20 mM EDTA) was added to each flask. Using a plastic scraper, the cells 
were scraped into the PBS-EDTA and then removed with a pipette. The suspension was 
placed in 15ml conical tubes and pelleted at 500 x g for 5 minutes. The PBS-EDTA was 
then discarded, and to the cell pellet was added 1 ml 1X PBS and the resuspended solution 
was transferred to a 1.5 ml eppendorf tube on ice. The eppendorf tubes were then 
microfuged for about 15 seconds to pellet the cells. Using a pipette tip, discard the wash to 
get rid of as much of the PBS as possible and place the tubes on ice. 
 
Cell Lysis 
Once all the PBS wash was removed, 1 ml of Complete Buffer-A (10 mM HEPES 
pH 7.9, 10 mM KCl, 1.5 mM MgCl2, and freshly added 0.5 mM DTT and 0.5 mM PMSF) 
was added to each pellet from one T-25 flask and the pellets were resuspended in this 
hypotonic buffer and incubated on ice for 15 minutes for thorough swelling of the cells. 50 
ul of 10% NP-40 was added to each 1 ml sample (to make 0.5% final concentration) gently 
mixed by inverting the tubes several times to lyse the cell membranes and not vortexing. 
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Nuclear Extraction 
The tubes were then microfuged for 30 seconds and the supernatant was discarded 
with a pipette tip to remove as much buffer as possible and samples were placed on ice. 50 
ul of the Complete Extraction Buffer (20 mM HEPES pH 7.9, 0.45 M NaCl, 1 mM EDTA 
pH 8.0, and freshly added 0.5 mM DTT and 0.5 mM PMSF) was added to each nuclear 
pellet from one T-25 cultured flask, resuspended thoroughly with a pipette tip and placed 
on ice for 10 minutes with intermittent vortexing. 
 
Lysate Clarification and Storage 
The nuclear suspension was then microfuged at 4°C for 5 minutes to pellet nuclear 
debris. The supernatant (containing nuclear proteins) was put into 0.5 ml eppendorf tubes 
(about 50 µl per tube) on ice and equal volume (50 ul) of Dilution Buffer (20 mM Hepes 
pH 7.9, 0.1 M KCl, 0.2 mM EDTA pH 8.0 and 20% Glycerol) was added to lower the salt 
concentration. The samples were vortexed to mix and 5 µl of the aliquot was put into 0.5 
ml of dH2O for protein determination (1:100) using Coomassie Reagent (Pierce) as 
described above.  The nuclear extract tubes were stored at –80˚C. 
 
Western Blots (Immunoblots) Analysis 
Western blots were used to analyze the levels of SOD protein in Neuro-2a whole 
cell lysates in inhibition experiments, and the levels of c-Jun and c-Fos proteins in Neuro-
2a nuclear extracts in AP-1 translocation experiments. 
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Gel Polymerization 
A BRL V-16 glass plate apparatus was assembled using two non-siliconized glass 
plates (the front plate being 6 x 8 inches, the back plate 6 x 6 inches), and 0.8 mm thick 
spacers, held secure with clamps around the edges of the plates. The first gel, a lower 
resolving gel, was poured first as the base layer. It was composed of 7.6 ml of distilled 
H2O, 6.7 ml of 30% acrylamide (2.7% cross linking), 5.1 ml of resolving gel buffer (1.5 M 
Tris-HCl, pH 8.0), 200 µl of 10% SDS, 400 µl of 5% ammonium persulfate, and 10 µl of 
TEMED (added just prior to pouring the gel as a catalyst). The solution was poured 
between the two plates to about 1.5 cm from the top. A thin layer of dH2O was overlayed 
on the top in order to make sure the lower gel was in a straight line. The gel was then 
allowed to polymerize for 20 minutes. 
 After the lower resolving gel had fully polymerized, the water was poured off and 
the upper stacking gel was poured on. The upper stacking gel was composed of 5.52 ml of 
distilled H2O, 1.67 ml of 30% acrylamide (2.7% crosslinking), 2.5 ml of stacking gel buffer 
(0.5 M Tris-HCl pH 6.8), 100 µl of 10% SDS, 200 µl of 5% ammonium persulfate, and 10 
µl of TEMED (added just prior to pouring the gel as a catalyst). The upper stacking gel was 
poured on top of the lower resolving gel until it reached the top of the smaller back glass 
plate. A 20-stall comb was then carefully placed between the two plates, about 0.5 cm into 
the upper stacking gel, making sure no air bubbles were near the comb teeth. The gel was 
then allowed to polymerize for another 20 minutes. If the gel was left overnight, the top of 
the plates was covered with plastic wrap to prevent desiccation. 
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Gel Electrophoresis 
 When the gel was completely polymerized, the clamps and the lower spacers were 
removed. After making sure that the black gaskets on the side spacers were pushed down, 
with no space between them and the top of the smaller plate, the plates were then mounted 
into the V-16 vertical electrophoresis unit, secured in place by clamps on both sides.  
Protein electrode buffer (25 mM Trizma Base, 0.192 M Glycine, 0.1% SDS) was then 
poured in the upper reservoir to check for leaks, if no leaks were present, then it was also 
poured in the lower reservoir until level with the electrodes. The comb was then removed, 
the wells were flushed out, and the gel was pre-run for one hour at 150 volts. After the pre-
run, the samples were prepared for electrophoresis by inserting them in a boiling water bath 
for two minutes, and then microfuging briefly. Samples were then loaded into each well (5 
µl loads were used per lane corresponding to 5 µg of protein unless otherwise noted), and 
electrophoresed for about 3 hours at 150 volts so that the dye traversed down ¾ of the gel. 
    
 Gel Transfer 
 After the 3 hours of electrophoresis, the side spacers were removed, and one of the 
glass plates was carefully removed. A notch was made in the original right corner of the 
gel, as an orientation aid, so the bands could be viewed in the correct order. The gel was 
trimmed to contain only the sample area, and then a nitrocellulose membrane (0.45 µm, 
BA-85, VWR Scientific) was cut to cover the gel (notched on the same side to match the 
notch in the gel). It was then surrounded on both sides by two pieces of 3 MM paper, all 
presoaked in transfer buffer (48 mM Trizma base, 39 mM Glycine, 0.037% SDS, and 20% 
Methanol) from the electroblotter. The gel/membrane sandwich was then placed in the 
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plastic electroblot holder (with sponges on either side), fastened shut, and placed in the 
electroblot unit, submerged in chilled transfer buffer. The nitrocellulose membrane side 
must face the positive anode to ensure proper protein transfer from the gel to the 
membrane. The membrane was then transblotted in the refrigerator at 4˚C, on a slow speed 
stir, for 2 hours at 50 volts. 
 
Membrane Blocking/Antibody Incubations 
 Once the membrane had been transblotted, it was removed from the unit and placed 
in a Tupperware hybridization tray for blocking. The side that originally was in contact 
with the gel was marked with a felt pen, and remained face up at all times. The membrane 
was blocked with 50 ml of freshly made chilled blocker (1X PBS, 1% Casein powder, and 
0.2% Tween-20) for one hour, mixing at low speed on the red rocker shaker. After the 
block, if the sample was to be tested for SOD, the blocker was replaced with fresh blocker, 
and 50 µl of the primary antibody (rabbit anti-SOD, Rockland [Penn], catalog #100-4191, 
main stock: 90 mg/ml) was added to the liquid, not directly onto the membrane. For c-Jun 
and c-Fos protein detection, 50 µl of primary c-Jun (rabbit anti-c-Jun polyclonal, Santa 
Cruz #SC-44, 200 µg/ml) and 50 µl of primary c-Fos (rabbit anti-c-Fos polyclonal, Santa 
Cruz #SC-52, 200 µg/ml) was added to the 50 ml blocker to make a final concentration of 
0.2 µg/ml. The membrane was then left again to mix as previously described for two hours.   
 After the incubation with the primary antibody, the solution was removed, and the 
membrane was washed twice in PBS-Tween, 2 minutes each time, at a vigorous rate on a 
gyratory shaker. Next, the membrane was incubated with 50 ml of fresh blocker 
supplemented with 50 µl of the secondary antibody (goat anti-rabbit-HRP, Pierce #31460, 
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final concentration: 0.4 µg/ml) for two hours on the red rocker shaker. After the two-hour 
incubation with the secondary antibody, the used solution was removed, and the membrane 
was washed four times (3 times in PBS-Tween, then once in 1X PBS) for 2 minutes each 
on the gyratory shaker at vigorous speed. 
 
Chemiluminescent Detection/X-ray Film Development 
  After the last washes, the membrane was moved from the hybridization tray 
to a piece of foil on the bench top, protein side up. In a 15 ml conical tube, the detection 
solution (5 ml Luminol/Enhancer Solution plus 5 ml Stable Peroxide Solution) was mixed.  
The freshly prepared solution was then poured on the membrane, and spread evenly with a 
glass pipette and allowed to incubate for 5 minutes. After 5 minutes, the membrane was 
picked up using tweezers, and the corner was dabbed with a Kimwipe to remove excess 
detection solution. The membrane was placed between two sheets of clear plastic 
Photogene Development Folders (Gibco BRL #18195-016), and any air bubbles were 
removed by rubbing a Kimwipe over the plastic surface. The folder was then placed in a 
film cassette without a screen for transportation to the darkroom for development.   
 Before developing, the development tank was filled with water at a constant 25°C 
maintained throughout development. Kodax X-Omat AR film was exposed to the 
membrane for ~30 seconds for SOD, or for ~ 20 minutes for c-Jun and c-Fos proteins. The 
film was then placed in the GBX developer, agitating initially to remove air bubbles, and 
left for 5 minutes. It was then removed, dipped briefly in the water to remove the 
developer, and submerged into the fixative solution for three minutes, with intermittent 
agitation over the entire 3 minutes. Finally, the film was placed in the water bath for 5 
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minutes to remove excess fixative, and hung to air dry. Bands were quantitated using 
Scionimage Software (NIH). 
 
Isolation of Total Cellular RNA From Mouse Neuroblastoma Cells For RT-PCR 
 Confluent neuroblastoma cultures were treated with 1.0 µg/ml of hEPN-1 
peptide for 24 hours, followed by RNA isolation. Total cellular RNA was isolated from the 
neuroblastoma cultures using the Clontech Atlas Pure Total RNA Labeling System (# 
K1038-1).  Table 3 summarizes the two neuronal cell samples tested in this thesis, and their 
corresponding RNA yields. 
 
Table 3 - Mouse Neuroblastoma Cell Sample Size and Corresponding RNA Yields 
Date Sample Flasks RNA Yield (µg) Conc. µg/µl 
03/29/2004 Ctrl One  T-150 100.8 2.5 
03/29/2004 hEPN-1 One  T-150 75.6 1.9 
 
 
Cell Collection 
 
The first step in the RNA isolation process was to use a plastic cell scraper to 
dislodge the cells from the bottom of the flask. The cell suspension was then poured into a 
15ml or 50ml plastic tube, and centrifuged in a clinical centrifuge for 5 minutes at about 
2,000 rpm (500 x g, medium setting) to pellet the cells. The supernatant was then 
discarded, leaving a small volume of medium for cell transfer. The pellet was resuspended 
in a small volume of the supernatant, and transferred into 2ml sterile eppendorf tubes.  
Typically 2ml eppendorf tubes were used for experiments using cell counts ranging from 
106 to 107 total cells. The tubes were then microcentrifuged for 30 seconds at 4˚C to pellet 
the cells. The supernatant was then thoroughly removed, sometimes spinning the tubes 
twice to remove extra supernatant. 
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Cell Lysis 
For a total cell count of 107 cells split between 2 eppendorf tubes, 0.25 ml of 
denaturing solution (1 M NaOH, 10 mM EDTA) was added to each cell pellet. The cells 
were re-suspended completely by pipetting up and down vigorously, and vortexing. The 
solution was then incubated on ice for 5-10 minutes, and then re-vortexed. The tubes were 
microcentrifuged at 12,000 rpm for 5 minutes at 4˚C in order to pellet cellular debris. 
Following centrifugation, the supernatant (a volume of approximately 0.5 ml) was removed 
and transferred to new sterile 2ml eppendorf tubes. 
 
Phenol Extraction 
A volume of 0.5 ml of TE-saturated phenol (an equal volume) was added to each 
tube. Tubes were securely closed and vortexed vigorously for one minute, then placed on 
ice for five minutes. 0.15 ml of chloroform was then added to each tube to make a total 
volume of 1.15 ml. The tubes were vortexed vigorously for one to two minutes, assuring 
that the tubes did not leak, and then placed on ice for five more minutes. After incubation 
on ice, the tubes were centrifuged at 12,000 rpm for ten minutes at 4ºC to separate aqueous 
and phenolic phases. Avoiding the white interphase and lower organic phase of the sample, 
the upper aqueous phase containing RNA (approximately 0.5 ml) was then transferred to a 
new sterile eppendorf tube. For samples expected to contain low amounts of RNA, 1 µl of 
20 mg/ml, glycogen was added to the sample to act as a carrier.    
 
 
 
 40
Isopropanol Precipitation 
A volume of 0.5 ml of isopropanol was slowly added to the 0.5 ml of supernatant in 
each tube and mixed. The tubes were incubated on ice for 10 minutes, and then centrifuged 
at 12,000 rpm for 15 minutes at 4ºC to the pellet the RNA. Once centrifuged, the 
supernatant was carefully removed and discarded, without disrupting the RNA pellet.  
 
Pellet Wash 
Then 0.25 ml of 70-100% ethanol was added to the pellet, the tube was vortexed, 
then centrifuged at 12,000 rpm for 5 minutes at 4ºC. Being very cautious to not disturb the 
loose RNA pellet now present, the supernatant was removed and discarded from each tube.  
The tubes were left on the bench allowing the pellets to air dry, or the vacuum drying 
apparatus was used to expedite the drying process. 
 
Pellet Dissolution 
Once the RNA pellet had completely dried, 40 µl of RNase-free dH2O water was 
added, producing an RNA concentration of 1-2 µg/µl. The tube was then heated at 50ºC for 
5 minutes, occasionally flipping the tube to dissolve the RNA. It was then briefly 
microfuged. For OD 260 analysis, 1 µl of the final solution was aliquoted and added to 1 
ml dH2O prior to UV spectrophotometry. The rest of the RNA was aliquoted into several 
eppendorf tubes (about 10 µl per tube) to avoid repeated freeze/thaw which degrades 
nucleic acids. The samples were stored at -80˚C for later use. 
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Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR) 
To test whether the mouse Neuro-2a RNA samples expressed genes of particular 
interest, RT-PCR was performed using a modified version of Amersham’s Two-Step RT-
PCR with Ready-To-Go RT-PCR beads (#27-9266-01) in 0.5ml eppendorf tubes. Each 
tube contained one bead containing lyophilized and stabilized buffer, dNTPs, Taq, and 
reverse transcriptase. All primers used were purchased from Fisher Sigma Genosys, and 
were designed for the mouse sequences using the BLAST program 
(http://www.ncbi.nlm.nih.gov/BLAST/). 
 
Reverse Transcription of the RNA 
 
 The following items were added to each 0.5 ml ready-to-go eppendorf tube 
containing one bead: 44 µl dH2O (flip the tube to dissolve the bead, do not vortex which 
can denature the enzymes), 2 µl of 50 µM antisense primer, and 2 µl of 1 µg/µl RNA 
template. This was gently mixed, spun briefly in a microcentrifuge at room temperature, 
and then incubated in the thermal cycler at 42˚C for 30 minutes to elongate, followed by 
95°C for 5 minutes to inactivate the reverse transcriptase. After this point, the samples 
could be stored at -20°C, or the procedure could continue to PCR.    
 
PCR  
The reaction tubes from the reverse transcription step (already containing the 
antisense primer) were spun briefly in a microcentrifuge at room temperature and 2 µl of 50 
µM PCR sense primer were added to make a 50 µl reaction. The samples were gently 
mixed, spun briefly, and then placed in the thermal cycler for the following program: 95°C 
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for 4 min initial denaturation, 32 cycles of 95°C for 30 seconds, annealing for 30 seconds 
(usually at 55°C unless otherwise stated), and elongation for 72˚C for 40 seconds.  Finally 
a polishing step was performed at 72˚C for 5 minutes. The samples were then stored at 4˚C 
overnight in the thermal cycler, or used immediately. 
 
Analysis of RT-PCR Reactions 
1 µl of 10x DNA loading dyes was mixed with 10 µl of the PCR reaction, and 10 µl 
of this 11 µl mixture was analyzed by electrophoresis on a 2.5% agarose gel in 1X TAE 
buffer, containing about 0.5 µg/ml of ethidium bromide. Since the TAE-based loading dye 
contained TAE as its buffer, the same TAE buffer was used to make the gel and electrode 
buffer. Gels were visualized under UV light. 
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RESULTS 
 
 The goals of this thesis project were to extend our knowledge of the mechanism of 
action of goldfish EPN mimetic CMX-8933, to use bioinformatic approaches to identify 
candidates for human EPN, and to test human EPN mimetics for biological activity. 
 
CMX-8933-Induced Upregulation of SOD Depends On AP-1 Activation in Rat 
Primary Cortical Cultured Cells 
The first part of the thesis investigated whether transcription factor AP-1 is required 
for CMX-8933’s upregulation of SOD, or whether its activation is merely concurrent. Our 
lab previously showed that CMX-8933 activates JNK kinase, phosphorylates the c-Jun 
component of AP-1, increases AP-1 translocation to the nucleus, increases AP-1’s DNA-
binding affinity, and increases the transactivation of an AP-1-dependent promoter (Adams 
et al, 2001). We also showed that CMX-8933 upregulates SOD (Parikh, 2003) and that this 
upregulation depends on the activation of three kinases in the MAPK / AP-1 pathway 
(PKC, PTK, MEKK) (Kaska, 2003) in rat primary cortical cells. 
 Inhibition experiments were performed using trifluoromethyl pyrimidine 
carboxylate (TFPC), a specific AP-1 inhibitor with an IC50 of 1.0 µM in neuronal cultures 
(Palanki et al, 2000).  Four independent SOD Western experiments were performed (Figure 
7) using whole cell lysates prepared from in vitro cultured rat primary cortical cells pre-
treated for 5 minutes with TFPC inhibitor before a 5 hour treatment with 10 ng/ml CMX-
8933. SOD protein levels were compared to a control with no treatment of peptide (lane 
“ctrl”, low SOD levels) and to cultures treated with 8933 but no inhibitor (lane “0”, high 
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SOD levels). SOD bands were quantified using Scionimage software, shown as histobars 
below each panel (fold increase relative to the untreated sample). As expected (Parikh, 
2003), the 10 ng/ml CMX-8933 treatment with no inhibitor (lane “0”) showed a dark SOD 
band at the expected size of SOD protein (34 kDa) that migrated just above the 31 kDa 
marker band. Increasing concentrations of TFPC inhibitor (0.1, 1.0, 10, 100 µM) produced 
less SOD activation, in a concentration-dependent manner. The results of the three 
additional independent experiments (panels B (experiments 2 & 3) and C (experiment 4)), 
show similar trends as panel A (experiment 1). 
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Figure 7 - TFPC Inhibitor of AP-1 Inhibits CMX-8933-Induced Increases in SOD Levels in Rat 
Primary Cortical Cells. Rat primary cortical cultures were pre-incubated with different concentrations of 
TFPC inhibitor (see Methods) for 5 minutes, then 10 ng/ml of CMX-8933 was added for a period of 5 hours.  
Panel A represents Experiment 1, while Panels B and C represent three additional experiments. Arrows to the 
right denote the positions of the 34 kDa SOD-1. Arrows to the left denote positions of the biotinylated 
marker. 
 
C 
B 
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The means of trials 1 through 4 for the in vitro inhibition experiment are illustrated 
in Figure 8, with error bars representing standard deviation. P values were calculated by 
Microsoft excel using a two-tailed T-test. Treatment of the rat primary cells with 10 ng/ml 
CMX-8933 for 5 hr increased SOD an average 14-fold relative to untreated, as expected 
(Parikh, 2003). No significant difference (p = 0.06) occurred between lanes “0” and “0.1 
µM”, indicating a low concentration of inhibitor had no significant effect on SOD levels.  
Statistically significant differences occurred at TFPC concentrations of 1.0 µM (p = 
0.0004), 10.0 µM (p = 0.001), and 100.0 µM (p = 0.001) relative to the uninhibited CMX-
8933-stimulated lane “0”. The statistically significant 67% reduction in SOD signal at the 
1.0 µM TFPC concentration occurred at the published IC50 for cultured neuronal cells 
where the inhibitor retains full specificity for AP-1. No significant difference (p = 0.81) 
occurred between lanes “10.0 µM” and “100.0 µM”, indicating the inhibitor’s effect was 
maximal at those concentrations. The data clearly demonstrate the requirement for AP-1 in 
CMX-8933’s activation of SOD. 
 
Figure 8 - Statistical Analysis of Four in Vitro SOD Inhibition Experiments. Histobars denote the means 
of four independent experiments. Error bars denote standard deviation calculated in Excel. P values were 
calculated using a student’s two-tailed T-test in Excel. Histobars 2 and 3 did not show significant difference 
(p = 0.06), whereas histobars 4, 5 and 6 showed significant differences in p values (p = 0.0004, p = 0.001 and 
p = 0.001, respectively) compared to the uninhibited CMX-8933-stimulated lane “0” (histobar 1). 
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Bioinformatic Verification of a Candidate for Human EPN 
The second part of this thesis investigated recent claims in the bioinformatics 
literature that EPN exists in species other than goldfish. Since our lab’s 1994 publication of 
the goldfish EPN sequence (Adams and Shashoua, 1994), over 30 fish and mammalian 
“EPN candidate” genes have been sequenced. Orti and Meyer (1996) aligned the amino 
acids sequences deduced from 25 fish EPN gene candidates to conclude that EPN primary 
amino acid sequences were not well conserved, but instead certain domains containing 
cysteine residues, and glycosylation sites were completely conserved in all 25 candidate 
fish EPN’s. This approach was recently extended (Apostolopoulos et al, 2001; Gregorio-
King et al, 2003) to deduce candidates for mammalian ependymin-related proteins 
(MERPs), including human EPN. We repeated these bioinformatic alignments to verify the 
conservation of key EPN domains in these candidates as shown in Figure 9 (Panels A, B 
and C).  
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 Figure 9 – Verification of Previous Bioinformatics Alignment Studies. Program MegAlign was used to 
align the EPN protein sequences of 31 species deposited in Genbank. Colors indicate areas of aminoacid 
identity (yellow), completely conserved domains (red), and strongly conserved domains (purple). Portions of 
the full-length sequence alignments are shown in panels A, B and C. Panel A also shows 7 of 8 aa of goldfish 
mimetic CMX-8933 (red, underlined) and two human EPN mimetics, hEPN-1 (7 of 8 aa, red underlined) and 
hEPN-2 (13 of 14 aa, blue box). Panel B indicates one of the two potential mammalian glycosylation sites. 
B 
C 
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 The analysis also included hydropathy plots which showed an amazing 
conservation in hydropathy profiles between human and goldfish EPN as shown in Figure 
10. 
 
 
Figure 10 – Hydropathy Analysis of Goldfish, Mouse and Human EPN. Kyte and Doolittle hydropathic 
profile comparison between goldfish and MERPs (mouse and human) ependymins. The vertical scale 
represents the hydropathic score for each amino acid, while the horizontal scale shows the amino acid 
position in goldfish. The heavy horizontal line in each profile represents an amino acid “score” of zero, with 
hydrophobic regions shown above the line, and hydrophilic regions shown below. The hydrophobic signal 
sequence and hydrophilic regions of goldfish EPN are denoted by pink arrows. 
 
 
Human EPN Peptide Mimetics hEPN-1 and hEPN-2 Induce AP-1 Translocation in 
mouse neuroblastoma cells. 
To test for potential biological activity of human EPN, we designed two human 
EPN peptide mimetics, hEPN-1 and h-EPN-2, based on our bioinformatic alignments. The 
former represents the same domain as goldfish CMX-8933 (strongly conserved in most fish 
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species, and with 3 residues perfectly conserved in all known EPN candidates), while 
hEPN-2 represents CMX-8933 plus 6 upstream aa (to include a perfectly conserved 
cysteine residue).   
As an assay to test “biological activity” we chose AP-1 translocation, since AP-1 
activation is clearly induced by goldfish CMX-8933, and translocation is a relatively easy 
to perform non-radioactive assay. Seven independent c-Jun, and five independent c-Fos, 
Western experiments were performed (Figures 11 and 13) using nuclear extracts prepared 
from in vitro cultured mouse neuroblastoma cells treated for 3 hours with various doses 
(0.1, 0.2, and 1.0 µg/ml) of hEPN-1 or hEPN-2. 
 
a) c-Jun Translocation 
c-Jun nuclear protein levels were compared to a control with no peptide treatment 
(Figure 11, lane “ctrl”) to determine the effectiveness of the treatment. The bands were 
quantified using Scionimage software, and the histobars shown below each panel indicate 
the fold increase relative to untreated sample. Both peptides induce a strong dose-
dependent increase in the nuclear levels of a c-Jun protein that migrates at the expected 39 
kDa size. These results were reproducible, the results of six additional independent 
experiments (Panels B, C and D) correlate nicely with experiment 1 (Panel A). 
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Figure 11 - Human EPN Mimetics hEPN-1 and hEPN-2 Increase c-Jun Translocation in Mouse Neuro-
2a Neuroblastoma Cells in a Dose-Dependant Manner. Mouse Neuro-2a cells were treated for 3 hours 
with various doses (listed) of hEPN-1 or hEPN-2, and nuclear extracts were analyzed by c-Jun immunoblot.  
Panel A represents trial–1. Panels B, C and D show the results of six additional experiments. Arrows on the 
right denote the positions of 39 kDa c-Jun protein. Arrows on the left denote the positions of biotinylated 
markers. Histobars represent the signal strength quantitated using Scion image software. 
 
The means of c-Jun experiments 1 through 7 are shown in figure 12. The figure 
shows that both peptides at the highest concentration tested (1.0 µg/ml) cause a statistically 
significant (p = 0.0001) average 12-15-fold increase in c-Jun levels over the untreated 
controls. There was little or no significant difference (p = 0.205) between the untreated 
samples and the low dose samples for both peptides. The medium dose (0.2 µg/ml) 
produced a significant difference (p = 0.001) compared to untreated samples. This data 
demonstrates that human EPN mimetics hEPN-1 and hEPN-2 increase nuclear levels of c-
Jun. 
 
Figure 12 - Statistical Analysis of Seven c-Jun Translocation Experiments. This data summarizes the 7 
experiments shown in figure 11. Histobars represent the means, and error bars denote standard deviations 
D 
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calculated in Excel. P values were calculated using a student’s two-tailed T-test in Excel. There was a 
significant difference between untreated versus medium dose samples (histobars 1 versus 3; and 1 versus 6) 
(p = 0.001), and  between the untreated versus high dose samples (histobars 1 versus 4; and 1 versus 7)  (p = 
0.0001). 
 
b) c-Fos Translocation 
Since the AP-1 particle activated by CMX-8933 includes c-Fos in addition to c-Jun 
(Adams et al, 2003), the ability of hEPN-1 or hEPN-2 to translocate c-Fos was also tested 
(Figure 13). This data (experiment-1 in panel A, experiment-2 in panel-B) was similar to 
that previously described for c-Jun. Three other experiments were also done (not shown).  
The c-Fos protein migrated at the expected size (62 kDa). 
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Figure 13 - Human EPN Mimetics hEPN-1 and hEPN-2 Increase c-Fos Translocation in Mouse Neuro-
2a Neuroblastoma Cells in a Dose-Dependant Manner c-Fos Translocation Experiments. Panel A 
represents experiment-1, while panel B shows experiment-2. Peptide stimulations were performed for 3 
hours. Three additional sets of the same experiment were also performed (data not shown). Arrows on the 
right denote the positions of 62 kDa c-Fos protein. Arrows on the left denote the positions of biotinylated 
markers.  Histobars represent the signal strength quantitated using Scion image. 
 
The means of the five c-Fos experiments are shown in figure 14. Both peptides at 
the highest concentration tested (1.0 µg/ml) cause a statistically significant (p = 0.002) 
average increase of 20-25-fold in c-Fos levels over the untreated controls. Little or no 
significant difference (p = 0.09) was seen between the untreated samples and low dose (0.1 
µg/ml) samples with either peptide. A substantial significant difference (p = 0.01) in c-Fos 
levels was found between untreated versus medium dose samples. 
 
B 
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Figure 14 - Statistical Analysis of Five c-Fos Translocation Experiments.  Histobars denote the means of 
5 independent experiments. Error bars denote standard deviations calculated in Excel. P values were 
calculated using a student’s two-tailed T-test in Excel. There was a significant difference (p = 0.012) between 
untreated and medium dose samples (histobars 1 versus 3; and 1 versus 6), and (p = 0.002) between the 
untreated and high dose samples (histobars 1 versus 4; and 1 versus 7). 
 
hEPN-1 Upregulates mRNAs Related To Growth And Translation 
The third part of this thesis was designed to determine whether treatment of mouse 
Neuro-2a neuroblastoma cultures with hEPN-1 increases the cellular titers of mRNAs 
related to growth and translation. We chose these areas to assay since previous data in our 
lab indicated treatment of rat primary cortical cultures with CMX-8933 upregulated 
mRNAs related to these functions (Kaska, 2003). In addition, a previous hybridization 
array performed in our lab (Parikh, 2003) indicated mRNAs for several ribosomal proteins 
increased in rat primary cortical cells treated with CMX-8933 (Table 4). 
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Table 4. Hybridization Array Summary Table for Ribosomal Proteins and EF-2 (Parikh, 2003). Bold 
text indicates candidate primers chosen for investigation in this thesis. +++ denotes a strong signal on the 
array, ++ is moderate, and  + denotes a weak signal. 
   
ARRAY 
COORDINATE 
GENBANK 
ACCESSION 
GENE/PROTEIN CLASSIFICATION ARRAY SIGNAL 
CTRL           8933 
C11g X62184 Ribosomal Protein L11 Ribosomal Protein + ++ 
C11h X78327 Ribosomal Protein L13 Ribosomal Protein + ++ 
C11j X53504 Ribosomal Protein L12 Ribosomal Protein + ++ 
C11k X51707 Ribosomal Protein S19 Ribosomal Protein + ++ 
C11L M27905 Ribosomal Protein L21 Ribosomal Protein + ++ 
C11m J02650 Ribosomal Protein 
L19 
Ribosomal Protein ++ +++ 
C12d K03502 Elongation Factor-2 Translation Factor ++ +++ 
 
  
Reverse transcriptase-polymerase chain reaction (RT-PCR) was used to assay levels 
of ribosomal protein L19 (Figure 15), translational elongation factor-2 (EF-2) (Figure 16), 
and energy-related ATP Synthase-C (Figure 17). Each assay was performed only once, so 
no positive conclusions can be drawn from the data, however the findings from each RT-
PCR experiment support our hypothesis that EPNs play a role in growth. In all 
experiments, the levels of housekeeper Polyubiquitin (amplicon size 231 bp) were equal 
between treated and untreated samples, while the levels of L19 mRNA (amplicon size 257 
bp), EF-2 mRNA (amplicon size 227 bp), and ATP Synthase-C mRNA (amplicon size 227 
bp) increased in hEPN-1-treated samples. 
 
 
Figure 15 - RT-PCR Analysis of L19 mRNA Levels in Mouse Neuroblastoma Cells Treated with hEPN-
1. Mouse Neuro-2a cells were treated for 24 hrs with 1 µg/ml hEPN-1, then RT-PCR was performed on total 
cellular RNA.  Polyubiquitin (amplicon size 231 bp, lower panel) was used as a housekeeper. The L19 signal 
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(amplicon size 257 bp, upper panel) was stronger in the hEPN-1-treated sample. This data correlates with the 
preliminary results obtained from the hybridization array. 
 
 
 
 
 
Figure 16 - RT-PCR Analysis of EF-2 mRNA Levels in Mouse Neuroblastoma Cells Treated with 
hEPN-1. Mouse Neuro-2a cells were treated for 24 hrs with 1 µg/ml hEPN-1, then RT-PCR was performed 
on total cellular RNA.  Polyubiquitin (amplicon size 231 bp, lower panel) was used as a housekeeper. The 
EF-2 signal (amplicon size 227 bp, upper panel) was stronger in the hEPN-1-treated sample. This data 
correlates with the preliminary results obtained from the hybridization array. 
 
 
 
 
Figure 17 - RT-PCR Analysis of ATP Synthase-C mRNA Levels in Mouse Neuroblastoma Cells 
Treated with hEPN-1. Mouse Neuro-2a cells were treated for 24 hrs with 1 µg/ml hEPN-1, then RT-PCR 
was performed on total cellular RNA. Polyubiquitin (amplicon size 231 bp, lower panel) was used as a 
housekeeper. The ATP Synthase signal (amplicon size 230 bp, upper panel) was stronger in the hEPN-1-
treated sample. This data correlates with the preliminary results obtained from the hybridization array. 
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DISCUSSION 
 
Transcription factor AP-1 was one of the first mammalian transcription factors 
identified (Angel and Karin, 1991), is activated in response to an incredible array of 
different stimuli (Wisdom, 1999), and is a central component of many signal transduction 
pathways. The term AP-1 actually refers to a family of related transcription factors whose 
members consist of dimers of the Jun and Fos family of proteins. Approximately 20 
different AP-1 versions have been characterized so far that explain, in part, AP-1’s diverse 
biological activities. The specific AP-1 upregulated by CMX-8933 consists of a c-Jun/c-
Fos heterodimer (Adams et al, 2003). Full-length neurotrophic factors (NTFs), such as 
Nerve Growth Factor, Neurotropin-3, and Brain-Derived Neurotrophic Factor promote the 
activation of AP-1 (Ip et al, 1993; Tong and Perez-Polo, 1996; Gaiddon et al, 1996), and in 
a positive feedback loop, AP-1 promotes their activation. Most importantly, AP-1 has been 
shown to function as a master-switch in short- to long-term synaptic plasticity, and long-
term memory consolidation (Sanyal et al, 2002). That finding, plus ours, showing that EPN 
activates AP-1, may indicate that AP-1 is a key component of EPN’s mechanism of action 
during its function in long-term neural plasticity (Shashoua and Moore, 1978; Schmidt, 
1987; Piront and Schmidt, 1988; Schmidt et al, 1995). 
Our laboratory studies EPN mimetic peptides whose sequences represent a small 
portion of full-length EPN. Treatment of rat primary cortical cultures with mimetic CMX-
8933, an 8 aa peptide based on a middle portion of goldfish EPN, was previously shown to 
upregulate therapeutic enzyme superoxide dismutase (SOD) (Parikh, 2003). The first part 
of this thesis tested whether our previously observed CMX-8933-induced SOD 
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upregulation depends on AP-1 activation. Previous inhibition experiments in our lab 
(Kaska, 2003) showed that the SOD upregulation depends on three key components of the 
MAPK pathway (PKC, PTK, and MEKK), so we hypothesized that AP-1 activation known 
to be downstream from these components may also be required for SOD upregulation. In 
order to test this we chose TFPC (Trifluoromethyl Pyrimidine Carboxylate), a specific AP-
1 inhibitor with a 50% inhibition concentration (IC50) of 1.0 µM in neuronal cells (Palanki 
et al, 2000). Although the complete mechanism of action of TFPC remains unknown, cells 
treated with this poison do not transactivate AP-1-dependent genes. The inhibition 
experiments in Figure 7 illustrate that inhibition of AP-1 with 1 µM (IC50 concentration) 
TFPC significantly decreased (p = 0.0004) CMX-8933’s induced SOD signal by 67%.  
Thus, CMX-8933-induced upregulation of SOD indeed depends on the activation of AP-1.  
In the future, these SOD activation pathway experiments could be extended utilizing 
specific kinase/substrate assays to determine which specific components of the PKC, PTK 
and MEKK families are involved in SOD upregulation. 
 Since our lab’s 1994 publication of the first EPN sequence in goldfish (Adams and 
Shashoua, 1994), approximately 30 EPN-related genes (and their deduced proteins) have 
been identified by bioinformatic approaches. Initially, the bioinformatic approach was 
applied to 25 fish species (Orti and Meyer, 1996), but was eventually used to identify 
mammalian EPN-related proteins (MERPs) (Apostolopoulos et al, 2001). Recently, the 
human MERP-1 sequence was completed, and its expression in hematopoietic progenitors, 
brain, cardiomyocytes and muscle was reported (Gregorio-King et al, 2002). Expression of 
an EPN (usually associated with neuronal re-growth) in heart cells was initially quite 
surprising given cardiomyocyte’s well known lack of growth in culture, but recent findings 
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demonstrate the expression of nerve growth factor (NGF), one of the best characterized 
NTFs, and its p75 receptor, in myocardium (Ieda et al, 2004; Zhou et al, 2004).  
 The second part of this thesis re-verified the bioinformatic alignments (Figures 9 
and 10) discussed above to convince ourselves that human EPN might indeed exist, then 
based on those alignments, two human EPN mimetics were designed to test for biological 
activity. My alignments (Figure 9) did indeed find the same conserved cysteine domains 
(among others) as previous studies, indicating that primary sequence is not well conserved 
in this EPN family of proteins, but perhaps shape or key aa residues are. Hydropathy 
comparisons of goldfish EPN versus human MERP-1 were strikingly similar (Figure 10). 
Two human EPN mimetics were designed, hEPN-1 (8 aa long, whose sequence domain is 
analogous to goldfish CMX-8933), and hEPN-2 (14 aa long, that extends 6 aa upstream of 
hEPN-1 to include a totally conserved cysteine residue). To test their potential biological 
activities, we chose an AP-1 translocation assay since it is relatively easy to perform, and is 
non-radioactive. The results (figures 11 through 14) indicate that treatment of mouse 
Neuro-2a cells with various doses (0.1, 0.2, and 1.0 µg/ml) of hEPN-1 or hEPN-2 induces a 
statistically significant dose-dependent translocation of c-Jun and c-Fos proteins to the 
nucleus. The c-Jun increases at the highest doses tested were 12-15-fold (p = 0.0001 hEPN-
1; p = 0.0004 hEPN-2). The c-Fos increases at the highest doses tested were 20-25-fold (p 
= 0.002 hEPN-1; p = 0.001 hEPN-2). No significant differences occurred between 
untreated versus low dose samples (c-Jun: p = 0.205 hEPN-1, 0.467 hEPN-2; c-Fos: p = 
0.09 hEPN-1, p = 0.161 hEPN-2). Also no significant differences were observed between 
hEPN-1 versus hEPN-2 peptides at any dose tested (for example at a 1 µg/ml dose 
comparison, p = 0.422 c-Jun, p = 0.189 c-Fos) indicating that both mimetics were equally 
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active, and that the extra 6 aa length of hEPN-2 does not result in greater activity. So the 
simplest hypothesis is that CMX-8933 and hEPN-1 contain a key receptor-binding element, 
and extra amino acids add nothing more. Thus, these two human EPN peptide mimetics 
stimulate AP-1 translocation in mouse neuroblastoma cells, a finding that represents the 
first reported biological activity for human EPN. 
 Future human EPN experiments could include the use of immunoprecipitation 
experiments to determine whether the translocated c-Jun and c-Fos proteins are linked 
together in one particle, as is the case for the AP-1 activated by CMX-8933 (Adams et al, 
2003). Additionally, other human mimetics could be designed based on other regions of the 
proposed human EPN sequence, DNA hybridization arrays could be used to facilitate the 
identification of activated genes, or transcription factor arrays could be used to identify 
transcription factors activated in addition to AP-1. 
Previously, it was shown that CMX-8933 upregulates mRNAs related to growth 
and translation in rat primary cortical cells (Kaska, 2003). The last portion of this thesis 
used RT-PCR to determine whether hEPN-1 activated similar mRNAs. Mouse Neuro-2a 
cells were treated for 24 hours with 1 µg/ml hEPN-1 (the highest dose tested in the AP-1 
translocation experiments), then RT-PCR was performed on total cellular RNA template 
for the following candidates: ribosomal protein L19, translational EF-2, and ATP Synthase-
C. Figures 15-17 show preliminary results (one trial each), indicating that each of these 
candidates is upregulated in response to hEPN-1 relative to housekeeper polyubiquitin. So 
hEPN-1 mimetic does indeed appear to upregulate mRNAs related to growth in mouse 
Neuro-2a cells.  
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Future RT-PCR experiments could include verifying these interesting preliminary 
findings, expanding the candidate list to include other growth-related mRNAs (such as L-
11 and S-19, which gave moderately increased signals on a hybridization array), or using 
inhibition experiments to test whether the activation of these growth-related genes requires 
AP-1 or the MAPK pathway. Perhaps a profile of growth-related genes could be created for 
hEPN-1, and compared to the profile induced by another NTF like NGF, to test the 
uniqueness of EPN as a NTF. 
The study presented here gives us a deeper understanding of the mechanism of 
action of EPN. The existence of mammalian MERPs opens up vast new research prospects.  
The expression of human MERP-1 in brain, heart, and muscle (Gregorio-King et al, 2002), 
and NGF in heart (Ieda et al, 2004; Zhou et al, 2004), indicates NTFs have broader roles 
outside the central nervous system, perhaps related to growth or regeneration of these 
tissues. Experiments will need to be performed to extend this understanding, including 
experiments to isolate and characterize the specific cell surface receptor(s), and 
investigating NTF signal transduction pathways in heart and muscle. 
In conclusion, the data presented in this thesis demonstrates that 1) the CMX-8933-
induced upregulation of SOD depends on AP-1 in rat cortical cultures, 2) a human EPN 
candidate exists (as identified by bioinformatics), 3) human EPN  peptide mimetics hEPN-
1 and hEPN-2 increase the nuclear titers of c-Jun and c-Fos proteins,  and 4) the mimetics 
may increase cellular levels of mRNAs related to growth (L19, EF-2, and ATP Synthase-
C). Human EPNs or their peptide mimetics may potentially be used for future treatments of 
neuronal (or even muscle or cardiac) degenerative diseases. 
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